Recent Updates — NYXH
Nyxoah reported preliminary third-quarter global net revenue of approximately €9.2 million, reflecting 19% sequential growth driven by a 29% increase in U.S. sales to €6.7 million. The company also announced that its ACCCESS pivotal study met efficacy endpoints for Complete Concentric Collapse patients and submitted a PMA supplement to the FDA to expand Genio’s indication. However, Nyxoah lowered its full-year 2026 revenue guidance to €33-€35 million from the previous range of €36-€40 million due to slower-than-expected commercial ramp-up in the U.S. market. The company ended the quarter with approximately €77.0 million in cash and financial assets.
Nyxoah SA announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding outgoing CEO Olivier Taelman. The leadership transition aims to accelerate U.S. commercial traction for Genio, a neuromodulation therapy for Obstructive Sleep Apnea following its FDA approval and launch in the United States. Liam Kelly brings over 25 years of MedTech experience, previously serving as Chairman, President, and CEO of Teleflex Incorporated until January 2026. Nyxoah is a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea through neuromodulation.
Nyxoah SA announced that Chief Financial Officer John Landry will step down effective October 2, 2026. The company appointed Loïc Moreau, currently President International and former CFO, as Interim CFO to ensure continuity during the search for a permanent successor. Nyxoah reaffirmed its full-year 2026 financial guidance, projecting worldwide net revenue between €36 million and €40 million, gross margins of 60% to 62%, total operating expenses of €99 million to €102 million, and non-GAAP cash operating expenses of €88 million to €90 million. Nyxoah is a medical technology company that develops neuromodulation treatments for Obstructive Sleep Apnea.
Nyxoah SA reported second quarter and first half 2026 financial results, securing $110 million in aggregate financing during Q2. Global net revenue reached €7.7 million in Q2, a 21% sequential increase, bringing H1 2026 total to €14.0 million compared to €2.4 million in the prior year period. U.S. commercial momentum drove a 22% sequential growth in U.S. net revenue to €5.2 million. The company activated 89 new high-volume accounts and trained 55 additional surgeons, resulting in 180 active accounts and 427 patients under prior authorization entering Q3. Cash and cash equivalents plus financial assets totaled €97.8 million at June 30, 2026. Nyxoah operates in the medical technology industry, developing and commercializing innovative solutions to treat Obstructive Sleep Apnea.
On June 17, 2026, Nyxoah SA received approximately $15.0 million (€13.8 million) from the second tranche of its existing loan facility with the European Investment Bank. Additionally, the company announced an extraordinary shareholders' meeting scheduled for July 9, 2026. Nyxoah SA is a medical device company that develops neuromodulation therapies.